Syndax Pharmaceuticals Inc (SNDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $850.77M
Last updated: Nov 17, 2026 at 11:06 AM ET
Syndax Pharmaceuticals Inc (SNDX) Stock Forecast
Analysts expect Syndax Pharmaceuticals (SNDX) to earn -$2.13 per share in the fiscal year ending Dec 31, 2026, on revenue of $316.36M. Of 12 analysts, 12 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 1.83, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 16.7% |
| Buy | 10 | 83.3% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 45.0%.
- Fiscal year ending Dec 31, 2026
- -$2.13
- EPS consensus, revenue $316.36M
- Fiscal year ending Dec 31, 2027
- -$0.78
- EPS consensus, revenue $458.76M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.13 | -$2.24 to -$1.96 | 7 | $316.36M | $308.83M to $332.89M | 9 |
| Dec 31, 2027 | -$0.78 | -$1.96 to $0.40 | 11 | $458.76M | $402.01M to $614.97M | 11 |
Quarterly Estimates
The EPS consensus rises from -$0.50 for the quarter ending Dec 31, 2026 to -$0.28 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.50 | -$0.59 to -$0.28 | 14 | $97.41M | $85.26M to $134.27M | 13 |
| Mar 31, 2027 | -$0.28 | -$0.42 to -$0.08 | 3 | $95.95M | $95.30M to $96.61M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 6 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 3 |
| Fiscal year ending Dec 31, 2027 | 1 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.91.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.13 | -$1.94 | -$1.95 | -$1.93 | -$1.91 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.78 | -$0.73 | -$0.85 | -$0.82 | -$0.45 | N/A |
| Quarter ending Mar 31, 2027 | -$0.28 | -$0.08 | -$0.07 | -$0.07 | -$0.07 | N/A |
Frequently Asked Questions About SNDX
What is the SNDX stock forecast?
Consensus analyst estimates put Syndax Pharmaceuticals's EPS at -$2.13 for the fiscal year ending Dec 31, 2026, on revenue of $316.36M. The consensus rating from 12 analysts is Buy.
How do analysts rate SNDX stock?
Of 12 analysts covering Syndax Pharmaceuticals, 2 rate it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SNDX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.13, with estimates from -$2.24 to -$1.96 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.78, with estimates from -$1.96 to $0.40 from 11 analysts.
What revenue do analysts expect from Syndax Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $316.36M, with estimates from $308.83M to $332.89M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $458.76M, with estimates from $402.01M to $614.97M.
How many analysts cover SNDX?
12 analysts rate Syndax Pharmaceuticals stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
SNDX pages: Overview, Earnings, Forecast, Financials, Competitors